Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 400 versus UROVIST SODIUM 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 400 versus UROVIST SODIUM 300.
CONRAY 400 vs UROVIST SODIUM 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays by blocking their passage, thereby enhancing radiographic contrast in imaging procedures.
Iodinated contrast agent that attenuates X-rays, improving visualization of vascular structures and organs during imaging.
0.5-1.0 mL/kg (up to 150 mL total) intravenously, maximum 150 mL per procedure.
Intravenous injection of 50-100 mL for contrast imaging, typically a single dose of 300 mg iodine/mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged significantly.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (GFR >90 mL/min). In renal impairment, half-life may be prolonged up to 10 hours or more, correlating with decreased GFR.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Primarily renal (glomerular filtration), with >90% of the administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent